Q2 FY24 Financial Highlights

Q2 FY24: Key Developments Consistent trajectory of improved profitability Financials Sales and EBITDA* Trajectory 47,421 49,392 40,912 42,446 43,303 LUPIN Complex Generics gSpiriva DPI Gaining momentum Diazepam Launched in Rectal Gel US Business Development • India: Acquired five legacy brands from Menarini and Ondero trademark France: Completed acquisition of Medisol Compliance • 18.7% 13.9% 14.4% 12.2% 10.6% Q2 FY23 Q3 FY23 Q4 Q1 FY23 FY24 FY24 Q2 US FDA Sales EBITDA margin Received EIR for Nagpur OSD and Mandideep unit 2 *excludes NCE, Fx and Other Income Others Successful inspection of Mexico site by COFEPRIS • Successful WHO inspection for Dabhasa 5

View entire presentation